AllSight
Companies · SRRK · Biological Products, (No Diagnostic Substances)

Scholar Rock Holding Corp (SRRK)

Scholar Rock Holding Corp (SRRK) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Scholar Rock Holding Corp (SRRK) stock — financials & valuation

Key numbers for Scholar Rock Holding Corp (SRRK): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 28/100 — a percentile rank of Scholar Rock Holding Corp’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$5.9B
EV / EBITDA-13.9×
Return on equity-161.0%
ROIC-3151.1%
Debt / equity0.8×
Dividend yield0.0%

Is Scholar Rock Holding Corp overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Scholar Rock Holding Corp’s own financial statements and shown as context, never as advice.

Sep 15, 2026Safety commitments disclosed
Scholar Rock corrects ISEMBYLD disclosure as FDA mandates pregnancy and fracture monitoring
Sep 14, 2026FDA approval
Scholar Rock wins FDA approval for ISEMBYLD, shifting the story to launch execution
Aug 6, 2026
FDA path remains on track, but the quarter itself merely met expectations
Aug 6, 2026
New $200 million ATM adds funding flexibility—and dilution overhang
Related companies in Biological Products, (No Diagnostic Substances)
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact